The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease

https://doi.org/10.1007/s10156-011-0303-5Get rights and content

Abstract

Despite recent advances in chemotherapy, the treatment of pulmonary Mycobacterium avium complex (MAC) disease remains unsatisfactory. Judging from its MIC, fluoroquinolones including gatifloxacin (GFLX) are expected to demonstrate efficacy against MAC disease. However, there have been few clinical studies using fluoroquinolones. Therefore, a prospective study to evaluate the clinical efficacy and safety of a fluoroquinolone-containing regimen for the treatment of pulmonary MAC disease was conducted. In this trial, patients with pulmonary MAC disease received protocol-guided combined chemotherapy with rifampin (RFP) and ethambutol (EB) plus either GFLX or clarithromycin (CAM). Adult patients who fulfilled the criteria of the ATS definition of pulmonary MAC disease were enrolled in this study. The patients provided their informed consent, and treatments were administered for 1 year. Of 27 patients enrolled from three facilities, 14 patients were treated with the CAM-containing regimen and 13 patients were treated with the GFLX-containing regime. Four patients did not complete the 1-year treatment because of adverse events. Nine patients (64.3%) in the CAM group and 11 patients (84.6%) in the GFLX group achieved eradication of pathogens. Adverse events were observed more frequently in the GFLX group than in the CAM group. However, there were no severe adverse events in either group. The long-term results showed a similar relapse rate between the CAM and GFLX groups. The fluoroquinolone-containing regimen demonstrated both high efficacy and relative safety for pulmonary MAC disease that was similar to that of the CAM-containing regimen, which is considered to be the standard regimen.

References (21)

There are more references available in the full text version of this article.

Cited by (29)

  • Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease

    2022, Respiratory Investigation
    Citation Excerpt :

    However, in clinical practice, FQs have been used as substitutes for RIF, or in cases of macrolide resistance. A prospective study comparing the efficacy and safety of gatifloxacin or CLR-containing regimens in combination with RIF and EMB showed a similar rate of culture conversion (11/13 vs. 9/14) in untreated patients with MAC-PD [89]. Therefore, the BTS guidelines recommended treatment administration of isoniazid or FQs in combination with RIF and EMB for patients with macrolide-resistant MAC-PD [62].

  • Tolerability, adverse events, and efficacy of treatment for Mycobacterium avium complex pulmonary disease in elderly patients

    2022, Journal of Infection and Chemotherapy
    Citation Excerpt :

    Therefore, the rate of treatment success in this study was less than that in the pooled analysis, but was comparative with those in 3 studies in Japan [11,29,30]. This agreement is probably because no patients was treated with 1000 mg/day CAM and only 8.6% of patients received streptomycin in this study, similar to the 3 studies in Japan [11,29,30]. There are some limitations in this study.

  • Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review

    2018, Chest
    Citation Excerpt :

    Of these, three studies were double-blind controlled studies: Kobashi et al,38 Milanés-Virelles et al,45 and Olivier et al.61 The treatment duration of patients with MAC-PD varied greatly, from 3 months, for example, in the study of Leventhal et al,44 up to at least 24 months in the studies of Kobashi and Matsushima,39 Murray et al,47 and Jenkins et al.33 In nine studies, treatment duration was reported to be 6 months22,26-28,45 or less23,44,57,61; in 16 studies overall (or at least for a separately notified proportion of patients), treatment duration was at least 12 months.25,29-31,33,34,37-40,46,47,50,52,54,55 Six hundred eleven patients with prior NTM treatment of the total of 2,376 patients with MAC (25.7%) were identified in 24 of the 42 included studies (57.1%).

  • Treatment of Mycobacterium avium complex pulmonary disease

    2024, Journal of the Korean Medical Association
View all citing articles on Scopus
View full text